Factors influencing the decision to discontinue treatment due to chemotherapy-induced peripheral neuropathy among patients with metastatic breast cancer: a best–worst scaling
When faced with the decision to discontinue treatment due to CIPN, women with mBC attributed more importance to survival and reducing the risk of long-term CIPN. Knowledge of what matters most to patients may assist with shared decision-making to optimize therapeutic outcomes in patients receiving neurotoxic chemotherapy.
Authors
- Rotana M. Radwan (ORCID: https://orcid.org/0000-0003-0061-0637)
- Vanessa B. Sheppard (ORCID: https://orcid.org/0000-0003-2874-6659)
- Teresa M. Salgado (ORCID: https://orcid.org/0000-0003-2708-7145)
- Erin Hickey (ORCID: https://orcid.org/0000-0002-4264-247X)
- John F. P. Bridges (ORCID: https://orcid.org/0000-0002-3082-5535)
- Hetal Vachhani
- Daniel L. Hertz (ORCID: https://orcid.org/0000-0003-0501-1035)
- Maryam B. Lustberg (ORCID: https://orcid.org/0000-0001-8559-5645)
Institutions
- Virginia Commonwealth University (US)
- University of Michigan (US)
- The Ohio State University Wexner Medical Center (US)
- Yale University (US)
- Virginia Commonwealth University Medical Center (US)
Publication Details
- Journal
- Supportive Care in Cancer
- Published
- 2025-05-10
- DOI
- https://doi.org/10.1007/s00520-025-09508-4
- Citations
- 1
- Primary Topic
- Cancer Treatment and Pharmacology
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- American Cancer Society
- National Institutes of Health
- National Cancer Institute